---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-033738"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2026-08-19T20:04:17+00:00"
generated_at: "2026-08-19T20:05:18.767495+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Crinetics supplements proxy disclosures amid shareholder lawsuits over Vertex merger

## Summary
- Three shareholder lawsuits filed Aug 6 & 17, 2026 in NY and CA allege misleading proxy disclosures; seek to block merger.
- Board unanimously reaffirms 'FOR' recommendation on merger and related proposals; special shareholder meeting set for Aug 28, 2026.
- Supplemental disclosures add J.P. Morgan and Leerink valuation analyses; updated projections show revenue rising to $1,057M by 2030E and $4,583M by 2035E.
- Advisor fees disclosed: J.P. Morgan ~$69.4M and Leerink ~$60.8M, largely contingent on $85.00/share deal closing.
- Company denies allegations, says proxy complies with law; voluntary supplements made to avoid nuisance and potential delays.

## SEC filing metadata
- accession: 0001140361-26-033738
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2026-08-19T20:04:17+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000114036126033738/0001140361-26-033738-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000114036126033738/ef20080494_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-033738
- JSON: https://secwatch.observer/filing/0001140361-26-033738.json
- Plain text: https://secwatch.observer/filing/0001140361-26-033738.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.